Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
•
Male Breast Cancer
Is it reasonable to use hypofractionation in early stage male breast cancer s/p lumpectomy?
What clinical and pathologic features - if any - would necessitate conventional fractionation?
Answer from: Radiation Oncologist at Community Practice
Absolutely the same as what we do for women with breast cancer.
Comments
Radiation Oncologist at Allegheny Health Network, Pittsburgh
Agreed, while we don't have an RCT for male breast...
Radiation Oncologist at SSM Cancer Center/St Louis CyberKnife
Taking this question further, can we assume that p...
6090
15916
Sign In
or
Register
to read more
12580
Related Questions
Would you recommend PMRT to a clinically node positive (biopsy proven axillary node and indeterminate single IMN node) BRCA positive patient with multiple medical co-morbidities including scleroderma and ILD who is treated with neoadjuvant chemotherapy (NAC) and mastectomy who converts to ypT0/ypN0?
Would you consider 5-fraction whole breast RT for a patient with multiple positive margins following lumpectomy for whom reexcision is not possible?
What is your preferred comprehensive nodal irradiation approach in non-metastatic breast cancer patients with underlying respiratory diseases or poor baseline respiratory function in light of the findings from the RadComp Trial?
Is FAST-Forward/ultra-hypofractionation suitable for an early-stage breast patient after a lumpectomy with oncoplastic reduction?
Have the 10-year results from UK FAST-Forward presented at ESTRO 2025 impacted your practice with regard to patient selection?
In what patients is it inappropriate to offer DCISionRT testing?
In a patient with T2N0 breast cancer with skin involvement s/p lumpectomy and negative margins, if you are offering whole breast radiation, would you bolus your tangent fields?
How do you weigh upfront nodal burden when deciding to omit PMRT in a patient with cN1, ypN0 disease after neoadjuvant chemo, mastectomy and ALND?
How do you optimally set a patient up for breast radiation therapy if you don't have access to a breast board or wing board?
Would a longstanding diagnosis of multiple sclerosis impact your radiation recommendations for a patient with breast cancer?
Agreed, while we don't have an RCT for male breast...
Taking this question further, can we assume that p...